Niagen Bioscience (NASDAQ:NAGE) Price Target Raised to $16.00

Niagen Bioscience (NASDAQ:NAGE) had its price objective boosted by Canaccord Genuity Group from $13.00 to $16.00 in a report published on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities analysts have also issued reports on the stock. Wall Street Zen lowered shares of Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 6th. Roth Capital reiterated a “buy” rating and issued a $23.00 target price (up previously from $10.00) on shares of Niagen Bioscience in a research report on Friday, June 6th.

Niagen Bioscience Stock Up 0.5%

Niagen Bioscience stock opened at $14.14 on Tuesday. The business’s 50-day moving average price is $9.11. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of 83.18 and a beta of 2.08. Niagen Bioscience has a one year low of $2.31 and a one year high of $14.49.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.